Quintrio
Home

IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES

Idexx Laboratories Inc

IDXX

Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.

Last trade $690.64
Day change -$10.01 (-1.43%)
Day range $690.01 – $708.34
Volume 180,709
Market cap $55.20B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$55.2B
Price / earnings
46.69×
Price / book
29.53×
Price / sales
11.84×
EV / sales
11.98×
EV / EBITDA
33.56×

Profitability

Earnings per share
$15.01
Return on assets
31.89%
Return on equity
63.25%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.45×
Current ratio
1.19×
Quick ratio
0.88×
Cash ratio
0.16×

Cash flow

Price / cash flow
38.79×
Price / free cash flow
42.2×
Free cash flow
$1.31B

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for IDXX, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$1.21B$1.22B$1.14B$1.09B$1.11B$1.11B$998.43M$954.29M
Cost of revenue$449.94M$437.5M$418.08M$432.47M$421.89M$414.73M$375.05M$383.63M
Gross profit$764.3M$779.09M$722.74M$658.11M$683.35M$694.73M$623.38M$570.66M
Selling, general and administrative$293.13M$288.09M$294.37M$275.68M$265.09M$259.79M$247.78M$251.25M
Research and development$68.82M$65.43M$65.79M$66.83M$63.42M$61.9M$59.06M$57.73M
Total operating expenses$361.95M$353.52M$360.15M$342.51M$328.51M$321.69M$306.85M$308.97M
Operating income$402.35M$425.57M$362.59M$315.61M$354.85M$373.05M$316.53M$261.69M
Interest expense-$7.46M-$10.18M-$7.74M-$9.21M-$10.66M-$11.32M-$7.67M-$7.5M
Income before taxes$399.33M$417.22M$355.44M$306.98M$344.77M$362.35M$310.08M$256.39M
Income taxes$82.18M$78.81M$77M$58.79M$70.16M$68.36M$67.41M$40.24M
Net income$317.15M$338.41M$278.45M$248.19M$274.61M$293.99M$242.68M$216.15M
Net income attributable to common shareholders$317.15M$338.41M$278.45M$248.19M$274.61M$293.99M$242.68M$216.15M
EBITDA$442.91M$466.62M$400.27M$354.33M$391.47M$408.82M$350.6M$295.39M
Basic earnings per share$4.02$4.29$3.50$3.11$3.43$3.66$2.98$2.64
Diluted earnings per share$4.01$4.27$3.47$3.08$3.40$3.63$2.96$2.62

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Should You Continue to Hold ALGN Stock in Your Portfolio?

Align Technology has gained 25.4% over the past year, outperforming the S&P 500, driven by Invisalign portfolio expansion into younger patients and complex cases, plus strategic DSO partnerships. However, the stock faces headwinds from currency volatility and intense competition from traditional braces and lower-priced clear aligner alternatives. The company holds a Zacks Rank #3 (Hold) with 2026 EPS estimates revised down 1.5% to $11.12.

Zacks Investment Research

Here's Why You Should Retain NVST Stock in Your Portfolio for Now

Envista Holdings (NVST) has gained 24% over the past year, outperforming its industry, driven by international expansion, new product launches, and strong earnings beats. The company achieved 9% adjusted EBITDA growth and 25% EPS growth. However, fierce competition, weakness in China sales, and foreign exchange headwinds pose risks to future revenue and margin expansion.

Zacks Investment Research

Should You Continue to Retain Bruker Stock in Your Portfolio?

Bruker Corporation (BRKR) is well-positioned for growth driven by strong diagnostics and biosystems revenue, favorable European demand, and a $140 million cost-savings target by 2026 aimed at expanding margins by 250-300 basis points. However, uneven U.S. academic demand, macroeconomic uncertainty, and trade policy volatility present headwinds. The stock carries a Zacks Rank #3 (Hold) rating with a 3.4% earnings yield.

Zacks Investment Research

Is Now the Right Time to Hold Labcorp Stock in Your Portfolio?

Labcorp Holdings (LH) has surged 48.2% year-to-date, driven by expansion in specialty testing markets, AI and automation initiatives, and six consecutive quarters of margin expansion. However, currency headwinds, intense competition, and acquisition-related execution risks could limit future growth. The company maintains a Zacks Rank #3 (Hold) with a 5% earnings yield.

Zacks Investment Research

3 Reasons Growth Investors Will Love Idexx (IDXX)

Idexx Laboratories (IDXX) is identified as a compelling growth stock opportunity, earning a Zacks Rank #2 (Buy) and Growth Score of A. The animal diagnostic and healthcare company demonstrates strong fundamentals including 14.4% projected EPS growth (above the 11.6% industry average), robust year-over-year cash flow growth of 18.4%, and positive earnings estimate revisions, positioning it well for potential outperformance.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Jun 16, 20152-for-1stock dividend
Nov 27, 20072-for-1forward split